Effect of switching from prior Nucleos(t)ide Analogue(s) to Tenofovir alafenamide on lipid profile and cardiovascular risk in patients with Chronic Hepatitis B

Show other versions (1)

Saved in:

Bibliographic Details
Main Authors:	Witchayaporn Praguylertluck, Apichat Kaewdech, Naichaya Chamroonkul, Teerha Piratvisuth, Pimsiri Sripongpun
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2025-01-01
Series:	PLoS ONE
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12112372/?tool=EBI
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Effect of switching from prior Nucleos(t)ide Analogue(s) to Tenofovir alafenamide on lipid profile and cardiovascular risk in patients with Chronic Hepatitis B.
by: Witchayaporn Praguylertluck, et al.
Published: (2025-01-01)

A nationwide population-based cross-sectional time series study of hospitalized chronic liver disease burden in Thailand from 2017 to 2022
by: Rungfah Saehan, et al.
Published: (2025-08-01)

Outcomes of switching from protease inhibitor-based antiretroviral therapy to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically suppressed adults with nucleos(t)ide analogue resistance– a phase IV randomised, open-label study (PIBIK study)
by: Collins Iwuji, et al.
Published: (2025-02-01)

Metabolic dysfunction-associated fatty liver disease (MAFLD) in the adult population attending a health check-up program in Thailand: prevalence and fibrosis status
by: Supinya Sono, et al.
Published: (2025-07-01)

Switching to Dolutegravir/lamivudine or Bictegravir/Emtricitabine/Tenofovir alafenamide. A comparative real-world study
by: Hernando Knobel, et al.
Published: (2023-12-01)

Observational pilot study of switching from entecavir to tenofovir alafenamide in patients with chronic hepatitis B
by: Takuya Matsubara, et al.
Published: (2025-01-01)

Monitoring the Effects of Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Switch for Tubulotoxicity in Highly Treatment-Experienced or in Very Sick Individuals Infected with HIV
by: Nicole Marie Lioufas, et al.
Published: (2018-06-01)

Comparison of lipid profile alterations in chronic hepatitis b patients receiving tenofovir alafenamide or tenofovir disoproxil fumarate
by: Shenglong Lin, et al.
Published: (2024-11-01)

Association of nucleos(t)ide analogue therapy with Parkinson disease in chronic hepatitis B patients
by: Jihye Lim, et al.
Published: (2025-04-01)

The Cost-Effectiveness of Tenofovir Alafenamide for Chronic Hepatitis B Virus in Taiwan
by: Elise Chia-Hui Tan, et al.
Published: (2025-03-01)

An Exploratory Pharmacogenetic Pilot Study of Two Reverse Transcriptase Inhibitors, Tenofovir Alafenamide Fumarate and Tenofovir Disoproxil Fumarate
by: Derek E. Murrell, et al.
Published: (2025-05-01)

Bictegravir/Emtricitabine/Tenofovir Alafenamide in Adults with HIV/HBV Coinfection: An Open-Label, Single-Arm, Safety and Efficacy Switch Study
by: Helena Kwakwa, et al.
Published: (2025-03-01)

Distinct virologic trajectories in chronic hepatitis B identify heterogeneity in response to nucleos(t)ide analogue therapy
by: Tingyan Wang, et al.
Published: (2025-01-01)

Switching to bictegravir/emtricitabine/tenofovir alafenamide from efavirenz/emtricitabine/tenofovir disoproxil in virologically suppressed people with HIV: findings from a non-randomized clinical trial (EBONY study)
by: Roberta Gagliardini, et al.
Published: (2025-09-01)

Metabolic Outcomes of Changing From Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine to Rilpivirine/Tenofovir Alafenamide/Emtricitabine: A Longitudinal Study
by: Ping‐Feng Wu, et al.
Published: (2024-12-01)

Tryptophan metabolic reprogramming modulates cytokine networks in nucleos(t)ide analogue-treated chronic hepatitis B patients
by: Xuedan Gao, et al.
Published: (2025-07-01)

Impact of nucleos(t)ide analogue therapy on the incidence of Alzheimer’s disease in patients with chronic hepatitis B virus infection
by: Jihye Lim, et al.
Published: (2025-04-01)

Brief communication: comparison of changes in metabolic parameters following antiretrovial therapy with treatment regimens containing tenofovir alafenamide and tenofovir disoproxil fumarate
by: Hamed Mirmoezzi, et al.
Published: (2025-03-01)

Improvement in renal function after switching from entecavir to tenofovir alafenamide in chronic hepatitis B patients with low estimated glomerular filtration rates
by: Liang Wang, et al.
Published: (2025-07-01)

Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues
by: Rui Huang, et al.
Published: (2025-07-01)

Effectiveness of glecaprevir/pibrentasvir in HIV/HCV-coinfected patients treated with bictegravir/emtricitabine/tenofovir alafenamide
by: Aleksandra Berkan-Kawińska, et al.
Published: (2024-07-01)

Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV
by: Eric S. Daar, et al.
Published: (2025-04-01)

Effectiveness and safety of tenofovir amibufenamide and tenofovir alafenamide in treating elderly patients diagnosed with decompensated hepatitis B cirrhosis: a retrospective cohort study
by: Xinye Qiu, et al.
Published: (2025-04-01)

Comparative effectiveness and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in patients with HBV-associated decompensated cirrhosis: insights from a retrospective analysis
by: Lu Chen, et al.
Published: (2025-08-01)

Tenofovir alafenamide is superior to tenofovir disoproxil fumarate and entecavir in cost-effectiveness of treatment of chronic hepatitis B in china with new volume-based procurement policy.
by: Yi Lin, et al.
Published: (2025-01-01)

Characterizing treatment interruptions in the OPERA cohort and virologic outcomes after resumption with bictegravir/emtricitabine/tenofovir alafenamide
by: Karam Mounzer, et al.
Published: (2025-07-01)

The efficacy and safety of Nucleos(t)ide analogues in patients with spontaneous acute exacerbation of chronic hepatitis B: a systematic review and meta-analysis.
by: Weiyan Yu, et al.
Published: (2013-01-01)

Real-world experience with nucleos(t)ide analogue therapy and patient survival rates in chronic viral hepatitis B treatment centers in Eritrea
by: Michael Berhe Solomon, et al.
Published: (2025-01-01)

Impact of nucleos(t)ide analogues on the risk of hepatocellular carcinoma in chronic hepatitis B patients: a time-dependent Cox regression analysis
by: Makoto Moriyama, et al.
Published: (2025-06-01)

Incidence and determinants of achieving HBsAg <100 IU/mL in HBeAg-negative CHB patients with nucleos(t)ide analogue treatment
by: Jian Wang, et al.
Published: (2025-08-01)

Response to: Comment on “48-Week Outcome after Cessation of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patient and the Associated Factors with Relapse”
by: Wen-xiong Xu, et al.
Published: (2019-01-01)

Health care providers' decision-making and early adoption of tenofovir alafenamide for HIV preexposure prophylaxis: An inductive qualitative study.
by: Elisabeth Merchant, et al.
Published: (2024-01-01)

Virological and Biochemical Effects of Tenofovir Alafenamide in Different Patient Groups With Chronic Hepatitis B Virus Infection in Real-World Cohort
by: Erdem Bektas, et al.
Published: (2025-01-01)

A real-world disproportionality analysis of Tenofovir Alafenamide (TAF): Data mining of the FDA adverse event reporting system (FAERS)
by: Chao Zhang, et al.
Published: (2025-01-01)

Relationship Between Nucleos(t)ide analogue antiviral response time and prognosis in Chronic Hepatitis B: conclusions depend on baseline viral load and HBeAg status
by: Jingtao Huang, et al.
Published: (2025-04-01)

Successful viral suppression in a two-year-old child with human immunodeficiency virus infection treated with bictegravir/emtricitabine/tenofovir alafenamide
by: Coskun Ekemen, et al.
Published: (2025-07-01)

Reply to: “Comment on “Lower incidence of hepatocellular carcinoma with tenofovir alafenamide in chronic hepatitis B: Evidence from a large-scale cohort””
by: Jisoo Lee, et al.
Published: (2025-05-01)

Real-World Analysis of Weight Gain and Body Mass Index Increase Among Patients with HIV-1 Using Antiretroviral Regimen Containing Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, or Neither in the United States
by: Bruno Emond, et al.
Published: (2022-02-01)

Impact of metabolic dysfunction on treatment responses to nucleos(t)ide analogues in chronic hepatitis B: a retrospective multi-center REAL-B cohort studyResearch in context
by: Rui Huang, et al.
Published: (2025-09-01)

Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) After A Viremic Event: A Pooled Analysis of Studies in People with HIV
by: Anton Pozniak, et al.
Published: (2025-04-01)